About 1 million people are living with multiple sclerosis in the U.S., and about 10% of those have PPMS, making it the least common form of the disease.
Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...
Please provide your email address to receive an email when new articles are posted on . Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary ...
OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment ...
Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks ...
New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis, but ...
TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) ...
GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone ® /Glatopa ® ). PPMS is characterized by continued worsening neurologic function ...
Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of ...
WASHINGTON (AP) — In a story March 27 about a new multiple sclerosis drug, The Associated Press reported erroneously that Novartis’ drug Gilenya was launched in March 2011. The drug was launched in ...
March 11 (Reuters) - The U.S. FDA has declined to approve Viatris (VTRS.O), opens new tab and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results